Tonix Pharmaceuticals (NASDAQ: TNXP) is a clinical-stage biotech with a history of reverse splits and pipeline pivots. The stock trades under 5 dollars, placing it in the most speculative corner of the market.
The Pipeline
Tonix has worked on treatments for fibromyalgia, migraine, and organ protection. Their lead candidate TNX-102 SL has been through multiple Phase 3 trials with mixed results. The company also has a vaccine program targeting COVID variants. This breadth reflects a strategy of pursuing any fundable indication.
The Approval That Changed the Story
In August 2025 the FDA approved TNX-102 SL as Tonmya for fibromyalgia - the first new approval for the condition in more than 15 years. Fibromyalgia affects an estimated 4 million American adults, most of them managed on older generics like pregabalin and duloxetine. Approval did not settle the debate: commercial execution, payer coverage and label positioning versus cheap generics now decide whether Tonix becomes a real revenue story or a one-event pop. The stock had already re-rated hard into and after the decision, textbook behavior for a sub-5 dollar biotech landing its first approval.
Competing in a Generic Market
The commercial hurdle is that fibromyalgia treatment is dominated by inexpensive generics. A branded sublingual tablet needs a clear tolerability story to win formulary placement, and specialty launches usually need several quarters before prescription trends mean anything. Early script data, not press releases, is the number to follow once a quarter closes.
The Reverse Split History
Tonix has executed multiple reverse splits to maintain NASDAQ listing requirements. Each reverse split reduces share count and mechanically raises the stock price. This is a signal of sustained operating losses and reliance on dilutive financing.
Warrants and the Cap Table
Read the share count history, not just the chart. Serial reverse splits followed by fresh issuance mean per-share value keeps getting divided even while the pipeline advances. Compare fully diluted shares today against two years ago before trusting any price target arithmetic on the name.
How Dilution Works Against You
Small biotechs fund themselves by selling stock. The sequence is predictable: a clinical win or regulatory decision lifts the price, and within days the company files an offering to monetize the strength. Warrants and at-the-market programs let management sell into retail enthusiasm continuously. Holders who bought the event often own a smaller share of a company they liked more a week earlier.
Trading TNXP on Chokcoin
TNXP is not an investment - it is a trading vehicle. Daily moves of 10-20 percent are routine. Binary events (clinical data, FDA decisions, financing announcements) can gap the stock 50 percent or more overnight.
On Chokcoin, TNXP trades at streaming quotes. Use bracket orders with wide stops if holding through binary events. Better approach: trade the momentum after the event, not the speculation before it.
Key levels: support at 2.80. Resistance at 4.20 then 5.50. Below 2.50, the stock enters delisting risk territory.
Rules for Binary Events
Decide the rule set before the catalyst arrives. Standard discipline: never more than 1 to two percent of the account in a pre-event position, no adding into the announcement, and an exit plan expressed as price levels rather than hopes. Sizing on the second move can be larger than on the first, because by then the direction has evidence behind it. Post-approval names reprice violently, then bleed for weeks as traders rotate - the second move is usually more tradeable than the first.
The honest assessment: Tonix is a lottery ticket that occasionally pays out. Trade it with money you can lose entirely. Do not confuse a speculative biotech trade with an investment thesis.
Current playbook on Chokcoin: track launch metrics each quarter - prescription trends, coverage decisions, and the size of any capital raise. A clean launch with contained dilution keeps the uptrend honest; a large offering below 4 dollars resets the board and the levels with it.